TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04118777

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 0.2 % Ropivacaine will be continuously administered intraperitoneally at a rate of 6 mL/hr

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: 0.2 % Ropivacaine will be continuously administered intraperitoneally at a rate of 6 mL/hr
Study: NCT02087137

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Memory and Aging Program
Study: NCT03089853

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Description: Bipolar self-adhesive neuromuscular stimulation electrodes will be placed over the quadriceps femoris muscle group. Stimulation pulses (30 Hz trains of 300 μsec biphasic pulses) will be delivered using the neuromuscular electrical stimulator. A 5 sec on/25 sec off work/rest ratio will be used initially, progressing to 10 sec on/30 sec off. The patient will be fully supported while knee extensions are performed as the participant sits in a chair. Current from the stimulator will be manually increased and determined by patient tolerance. The goal for each patient will be to reach the highest tolerable amplitude (up to 100mA). Training will be performed on each quadriceps femoris muscle, 30 minutes/day, for 2 weeks including hospital stay till return to the COPD Clinic. This will be followed by pulmonary rehabilitation exercises delivered at home via a smart phone for an additional 10 weeks. Rehabilitation will involve aerobics, strength training as well as breathing exercises.
Study: NCT02397343

Intervention type: DRUG
Group type: OTHER
Intervention: Hyperbaric oxygen

Intervention type: DRUG
Group type: OTHER
Intervention: Hyperbaric oxygen
Study: NCT01181609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks according to the chemotherapy regimen
Study: NCT02330276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (+)-Epicatechin
Description: The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (+)-Epicatechin
Description: The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (+)-Epicatechin
Description: The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.
Study: NCT02619526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Nebivolol 10mg, once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Carvedilol 25mg, twice a day
Study: NCT01509443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will perform 2-4 sessions of the prescribed exercise every day (One session: deep breathing 5-10 times; upper body stretching 5-10 times).
Study: NCT03837483

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OTL-103
Description: Autologous hematopoietic stem cells collected from mobilized peripheral blood transduced ex vivo with a lentiviral vector encoding the WAS cDNA
Study: NCT04533009

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: spine surgery
Description: Tramadol-paracetamol 325mg/37,5mg two tablets twice daily

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spine surgery
Description: Tramadol-paracetamol 325mg/37,5mg two tablets twice daily
Study: NCT02450890

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo First, then ORADUR®
Description: ORADUR®-Methylphenidate is available in three dosage forms (22mg, 33mg or 44mg). The optimal dose for each subject will be determined in the open-label titration period. After randomization, subjects will be subjected to the 4-week double-blind two-way cross-over treatment phase with 2 study periods (2 weeks of placebo and 2 weeks of ORADUR®-Methylphenidate oral capsule at the optimal dose, according to a pre-determined randomization schedule).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORADUR® First, then Placebo
Description: ORADUR®-Methylphenidate is available in three dosage forms (22mg, 33mg or 44mg). The optimal dose for each subject will be determined in the open-label titration period. After randomization, subjects will be subjected to the 4-week double-blind two-way cross-over treatment phase with 2 study periods (2 weeks of placebo and 2 weeks of ORADUR®-Methylphenidate oral capsule at the optimal dose, according to a pre-determined randomization schedule).
Study: NCT04596605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T2309
Description: Food for Special Medical Purpose / 4 capsules daily for 12 weeks
Study: NCT05061433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Integrated Healthcare/Community Paramedicine (MIH/CP) Support
Description: MIH/CP provider and their team will offer additional support and connection to resources after patient is discharged from hospital.
Study: NCT02087943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Orally twice a day (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Orally twice a day (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Orally twice a day (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Orally twice a day (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Orally twice a day (BID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally twice a day (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Orally twice a day (BID)
Study: NCT04596605

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrof Total
Description: 2 capsules daily for 12 weeks
Study: NCT04171245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laughie laughter prescription
Description: Creation of a Laughie; laughing with their Laughie 3x a day

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sleep tracking equipment
Description: Tracking sleep using equipment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleep tracking equipment
Description: Tracking sleep using equipment
Study: NCT01200277

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous vertebroplasty
Description: Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine. For the vertebroplasty procedure, 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the PMMA reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham procedure
Description: Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine. During the sham intervention, verbal and physical cues, such as pressure on the patient's back, are given, and the methacrylate monomer is opened to simulate the odor associated with mixing of cement, but the needle is not placed and cement is not injected.
Study: NCT04050579

Intervention type: DEVICE
Group type: OTHER
Intervention: on-pump intracardiac echocardiography
Description: Subjects will be patients with hypertrophic cardiomyopathy with interventricular septae less than 2.0cm who are undergoing septal myectomy. The patients will have already had a number of preoperative transthoracic echocardiographs as part of their normal hypertrophic cardiomyopathy care. Before cardiopulmonary bypass, the basal anterior septal thickness will be measured by transesophageal echocardiograph as is performed in all septal myectomy procedures. The Principal Investigator will then use the OPIE probe to measure the anterior basilar septal thickness. Myectomy will be performed and OPIE will be repeated. The post-myectomy anterior basilar septal thickness will again be measured by transesophageal echocardiography.
Study: NCT03394625

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Socket shield technique
Description: Socket shield technique is a recent technique which is by sectioning the root and extraction of palatal part and leaving buccal part of the root with its attachment of periodontal ligament and vascularization still intact then placing implant in palatal socket.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: using Xenograft material
Description: placing xenograft material in gap between the implant and the buccal plate of bone
Study: NCT04008485

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Electric Impedance Spectroscopy Device to predict PTB
Description: During this phase, we will measure MIS in 100 women at high risk of PTB (Group 1) and 100 women with symptoms of PTB to confirm its predictive potential for PTB. To determine whether MIS assessment could prove a platform technique for other tests and treatments within existing antenatal care pathways for PTB, we will also assess vaginal swabs for fFN and measure cervical length (CL) by ultrasound.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Electric Impedance Spectroscopy Device to predict PTB
Description: During this phase, we will measure MIS in 100 women at high risk of PTB (Group 1) and 100 women with symptoms of PTB to confirm its predictive potential for PTB. To determine whether MIS assessment could prove a platform technique for other tests and treatments within existing antenatal care pathways for PTB, we will also assess vaginal swabs for fFN and measure cervical length (CL) by ultrasound.
Study: NCT01438931

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DA-9501
Description: Dexmedetomidine hydrochloride variable dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DA-9501
Description: Dexmedetomidine hydrochloride variable dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03666949

Intervention type: DRUG
Group type: OTHER
Intervention: All General anesthesia
Description: Use of a hypnotic(propofol 2.5mg/kg), morphine(remifentanil1yg/kg) and curare(atracurium0.5mg/kg), with the support of orotracheal intubation and mechanical ventilation

Intervention type: DRUG
Group type: OTHER
Intervention: All Locoregional anesthesia
Description: Use of a local anesthetic( xylocaine 1%) for the realization of scalp nerve block
Study: NCT02772146

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLS UF
Description: One single ultrafiltration session of 10 hours.
Study: NCT00703118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Participants will receive telaprevir tablets of 750 mg orally eight hourly for 12 weeks in group A and B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Participants will receive telaprevir tablets of 750 mg orally eight hourly for 12 weeks in group A and B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFN-alfa-2a
Description: Participants will receive 180 µg subcutaneous (under the skin) injection of Peg-IFN-alfa-2a once weekly for 48 weeks in Group A, B and C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFN-alfa-2a
Description: Participants will receive 180 µg subcutaneous (under the skin) injection of Peg-IFN-alfa-2a once weekly for 48 weeks in Group A, B and C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFN-alfa-2a
Description: Participants will receive 180 µg subcutaneous (under the skin) injection of Peg-IFN-alfa-2a once weekly for 48 weeks in Group A, B and C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Participants will receive ribavirin tablets of 1000-1200 mg orally twice daily for 48 weeks in Group A, B, and C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Participants will receive ribavirin tablets of 1000-1200 mg orally twice daily for 48 weeks in Group A, B, and C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Participants will receive ribavirin tablets of 1000-1200 mg orally twice daily for 48 weeks in Group A, B, and C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive telaprevir matching placebo tablets orally for 4 weeks in Group A and B. Participants will receive telaprevir matching placebo tablets orally for 16 weeks in Group C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive telaprevir matching placebo tablets orally for 4 weeks in Group A and B. Participants will receive telaprevir matching placebo tablets orally for 16 weeks in Group C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive telaprevir matching placebo tablets orally for 4 weeks in Group A and B. Participants will receive telaprevir matching placebo tablets orally for 16 weeks in Group C.
Study: NCT02204098

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mammaglobin-A DNA Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mammaglobin-A DNA Vaccine
Study: NCT03006263

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Totally Laparoscopic Total Gastrectomy
Description: After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy,Totally Laparoscopic Total Gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
Study: NCT02204098

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Optional biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optional biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Optional biopsy
Study: NCT03006263

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopy Assisted Total Gastrectomy
Description: After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy,Laparoscopy Assisted Total Gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
Study: NCT01519973

Intervention type: RADIATION
Group type: OTHER
Intervention: SPECT/CT processed with Evolution for CardiacTM software
Description: SPECT/CT to be compared with PET/CT
Study: NCT02756364

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant IM injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant IM injection.
Study: NCT02204098

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optional biopsy
Study: NCT02727257

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MIRT
Description: MIRT consists of a 4-week physical therapy that entails four daily sessions, five days a week, in a hospital setting. The duration of each session, including recovery periods, is about one hour. The first session comprise cardiovascular warm-up activities, relaxation, muscle-stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes aerobic exercises to improve balance and gait using a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in day living activities. The last session includes one hour of speech therapy.
Study: NCT00097838

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVX101
Description: Alphavirus replicon particle vaccine expressing HIV Gag antigen
Study: NCT02756364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant IM injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Sapanisertib capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Sapanisertib capsule.
Study: NCT03593187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cal-1 (LVsh5/C46) drug product
Description: Autologous CD34+ Haematopoietic Stem/Progenitor Cells and CD4+ T Lymphocytes Transduced with LVsh5/C46, a Dual Anti-HIV Gene Transfer Construct
Study: NCT04677452

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JWCAR129
Description: Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR129. During JWCAR129 production, participants may receive bridging chemotherapy for disease control. Following successful generation of JWCAR129 product, participants will receive a course of lymphodepleting chemotherapy followed by one dose of JWCAR129 administered intravenously (IV).
Study: NCT00530790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropinirole controlled release (CR)-RLS
Description: White film-coated round-shaped tablet
Study: NCT01842906

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theravent
Description: nasal EPAP device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Sham device without EPAP
Study: NCT02650700

Intervention type: RADIATION
Group type: OTHER
Intervention: spleen radiotherapy
Description: Radiation: spleen radiation In Experimental arm, combine spleen radiation with chemotherapy. In Chemotherapy alone arm, the subjects should also receive spleen radiation once there is a severe CIT (≧grade III) during chemotherapy after radomization.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: spleen radiotherapy
Description: Radiation: spleen radiation In Experimental arm, combine spleen radiation with chemotherapy. In Chemotherapy alone arm, the subjects should also receive spleen radiation once there is a severe CIT (≧grade III) during chemotherapy after radomization.
Study: NCT02005900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) administration to modulate Triglycerides in HIV patients under HAART
Description: Multicenter, prospective, double-blind, randomized study of 48 weeks duration, in which the effect of 4 g daily of DHA vs 4 g daily of placebo (oleic acid) are studied on modulation of the Triglycerides and other lipids in patients with HIV infection under HAART treatment.
Study: NCT01399489

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Participants receive 16 weeks of moderate intensity aerobic training under the supervision of personal trainers. Each session lasts from 15 to 55 minutes depending upon patient tolerance
Study: NCT03970200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penn Microbiome Therapy - 001
Description: Fecal Microbiota for Transplant, enema product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penn Microbiome Therapy - 002
Description: Fecal Microbiota for Transplant, suspension product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penn Microbiome Therapy - 003
Description: Fecal Microbiota for Transplant, capsule product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: Standard of care antibiotics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: Standard of care antibiotics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: Standard of care antibiotics
Study: NCT03433859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: OnabotulinumtoxinA in intradermal Injections on residual lower limb : 100 Units - 1 dose

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Topical Aluminium Chloride (cosmetic product)
Description: Topical Aluminium Chloride (cosmetic product) : 1 quantity sufficient on the lower limb
Study: NCT04084899

Intervention type: DEVICE
Intervention: Continuous Positive Airway Pressure therapy
Description: Standard treatment with continuous positive airway pressure
Study: NCT01335854

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based Access to CPAP Data
Description: Participants will have web-based access to their CPAP usage for each 24 hours of treatment. They will be asked to view this data each day during the first week of the study, and then as frequently as they choose after the first week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based Access to CPAP Data with Financial Incentive
Description: Participants will have web-based access to their CPAP usage for each 24 hours of treatment. They will be asked to view this data each day during the first week of the the study, and then as frequently as they choose after the first week. There will be a payment of $30 during the first week for each day a participant uses CPAP for more than 4 hours the previous night and logs on to the website.
Study: NCT03173261

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Genexpert
Description: diagnosis of tuberculous pleural effusion and genitourinary tuberculosis by Genexpert by urine and pus and pleural fluid aspirate
Study: NCT02250950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI and SDT Exercise Group
Description: The intervention group will participate in a group exercise class that will be held once a week for an hour. This class will be taught by an instructor trained in MI and SDT. This individual will lead group discussions and will have the participants exercise together.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Non-MI and SDT Exercise Group
Description: This group will participate in a group exercise class that will be held once a week for an hour. This class will be taught by an instructor who was not trained in MI and SDT. This individual will lead a regular exercise class.